Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Development of Dual ARV-825 and Nintedanib-Loaded PEGylated Nano-Liposomes for Synergistic Efficacy in Vemurafnib-Resistant Melanoma
Yige Fu, Aishwarya Saraswat, Zeng-Hui Wei, et al.
Pharmaceutics (2021) Vol. 13, Iss. 7, pp. 1005-1005
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy
Shreyas Gaikwad, Manas Yogendra Agrawal, Itishree Kaushik, et al.
Seminars in Cancer Biology (2022) Vol. 86, pp. 137-150
Closed Access | Times Cited: 112
Drug delivery challenges and formulation aspects of proteolysis targeting chimera (PROTACs)
Aishwarya Saraswat, Richa Vartak, Rehab Hegazy, et al.
Drug Discovery Today (2022) Vol. 28, Iss. 1, pp. 103387-103387
Open Access | Times Cited: 38
Biphasic burst and sustained transdermal delivery in vivo using an AI-optimized 3D-printed MN patch
Arvind Bagde, Satyanarayan Dev, Lalitha Madhavi Konila Sriram, et al.
International Journal of Pharmaceutics (2023) Vol. 636, pp. 122647-122647
Open Access | Times Cited: 30
Human Solid Tumors and Clinical Relevance of The Enhanced Permeation and Retention Effect: A ‘Golden Gate’ for Nanomedicine in Preclinical Studies?
Poonam Gawali, Aishwarya Saraswat, Shruti Bhide, et al.
Nanomedicine (2023) Vol. 18, Iss. 2, pp. 169-190
Closed Access | Times Cited: 29
Heterotypic tumor spheroids: a platform for nanomedicine evaluation
Faezeh Vakhshiteh, Zeinab Bagheri, Marziye Soleimani, et al.
Journal of Nanobiotechnology (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 23
Recent Advances in Liposomes Efficacy as a Drug Delivery Platform for Melanoma Treatment
Elham Zarenezhad, Zahra Kazeminejad, Mahsa Rostami Chijan, et al.
Russian Journal of Bioorganic Chemistry (2025) Vol. 51, Iss. 1, pp. 93-116
Closed Access | Times Cited: 1
Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy
Yujeong Moon, Seong Ik Jeon, Man Kyu Shim, et al.
Pharmaceutics (2023) Vol. 15, Iss. 2, pp. 411-411
Open Access | Times Cited: 21
Advanced Delivery Strategies of Nintedanib for Lung Disorders and Beyond: A Comprehensive Review
D. Thakkar, Sanskriti Singh, Sarika Wairkar
AAPS PharmSciTech (2024) Vol. 25, Iss. 6
Closed Access | Times Cited: 6
Bioavailability enhancement of vitamin E TPGS liposomes of nintedanib esylate: formulation optimization, cytotoxicity and pharmacokinetic studies
Shabari Girinath Kala, Santhivardhan Chinni
Drug Delivery and Translational Research (2022) Vol. 12, Iss. 11, pp. 2856-2864
Closed Access | Times Cited: 24
MYC in liver cancer: mechanisms and targeted therapy opportunities
Furong Liu, Zhibin Liao, Zhanguo Zhang
Oncogene (2023) Vol. 42, Iss. 45, pp. 3303-3318
Closed Access | Times Cited: 15
PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities
Xuelian Liu, Anjin Wang, Yuying Shi, et al.
Molecules (2023) Vol. 28, Iss. 3, pp. 1217-1217
Open Access | Times Cited: 13
Oral lipid nanocomplex of BRD4 PROteolysis TArgeting Chimera and vemurafenib for drug-resistant malignant melanoma
Aishwarya Saraswat, Richa Vartak, Rehab Hegazy, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 168, pp. 115754-115754
Open Access | Times Cited: 13
Potential of the nanoplatform and PROTAC interface to achieve targeted protein degradation through the Ubiquitin–Proteasome system
Hanshu Xie, Chao Zhang
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116168-116168
Closed Access | Times Cited: 5
Hyaluronic acid-conjugated gliadin nanoparticles for targeted delivery of usnic acid in breast cancer: An in vitro / in vivo translational study
Mehrnaz Farzan, Jaleh Varshosaz, Mina Mirian, et al.
Journal of Drug Delivery Science and Technology (2023) Vol. 84, pp. 104459-104459
Closed Access | Times Cited: 11
Nanohybrid Based on (Mn, Zn) Ferrite Nanoparticles Functionalized With Chitosan and Sodium Alginate for Loading of Curcumin Against Human Breast Cancer Cells
Fatemeh Ahmadi, Majid Saeedi, Jafar Âkbari, et al.
AAPS PharmSciTech (2023) Vol. 24, Iss. 8
Open Access | Times Cited: 11
Nano-Proteolysis Targeting Chimeras (Nano-PROTACs) in Cancer Therapy
Yue Song, Qing‐Qing Dong, Yi-Ke Ni, et al.
International Journal of Nanomedicine (2024) Vol. Volume 19, pp. 5739-5761
Open Access | Times Cited: 4
Novel gene therapy for drug-resistant melanoma: Synergistic combination of PTEN plasmid and BRD4 PROTAC-loaded lipid nanocarriers
Aishwarya Saraswat, Hari Priya Vemana, Vikas V. Dukhande, et al.
Molecular Therapy — Nucleic Acids (2024) Vol. 35, Iss. 3, pp. 102292-102292
Open Access | Times Cited: 4
Synergistic breast cancer therapy with RGD-decorated liposomes co-delivering mir-34a and cisplatin
Hassan Bardania, Marzieh Baneshi, Reza Mahmoudi, et al.
Cancer Nanotechnology (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
Targeting BRD4 ameliorates experimental emphysema by disrupting super-enhancer in polarized alveolar macrophage
Difei Li, Xingming Shi, Yuqiong Yang, et al.
Respiratory Research (2025) Vol. 26, Iss. 1
Open Access
Development and optimization of a high-throughput LC-MS/MS method for the simultaneous determination of Exatecan and its Cathepsin B-sensitive prodrug, and ARV-825 in rat plasma: Application to pharmacokinetic study
Xiaolong Xu, Yangyang Liu, Yan Qing, et al.
Journal of Pharmaceutical and Biomedical Analysis (2025) Vol. 258, pp. 116746-116746
Closed Access
PROTAC Delivery Strategies for Overcoming Physicochemical Properties and Physiological Barriers in Targeted Protein Degradation
Endry Wahyu Syahputra, Hyunji Lee, Hyuk Jun Cho, et al.
Pharmaceutics (2025) Vol. 17, Iss. 4, pp. 501-501
Open Access
Inhalable dry powder containing lipid polymer hybrid nanoparticles of Nintedanib esylate: In vitro and in vivo evaluations
Mitali Patel, Sneha Karampuri, Vrushti Kansara, et al.
Journal of Drug Delivery Science and Technology (2023) Vol. 86, pp. 104716-104716
Closed Access | Times Cited: 10
Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions
Rajamanikkam Kamaraj, Subhrojyoti Ghosh, Souvadra Das, et al.
Bioconjugate Chemistry (2024) Vol. 35, Iss. 8, pp. 1089-1115
Open Access | Times Cited: 3
Efficient Delivery of Gold Nanoparticles and miRNA-33a Via Cationic PEGylated Niosomal Formulation to MCF-7 Breast Cancer Cells
Seyedeh Melika Ahmadi, Mohammad Seyedabadi, Pedram Ebrahimnejad, et al.
AAPS PharmSciTech (2024) Vol. 25, Iss. 7
Open Access | Times Cited: 3
Palmitoyl Carnitine-Anchored Nanoliposomes for Neovasculature-Specific Delivery of Gemcitabine Elaidate to Treat Pancreatic Cancer
Akanksha Patel, Aishwarya Saraswat, Harsh Patel, et al.
Cancers (2022) Vol. 15, Iss. 1, pp. 182-182
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top